Spatial, temporal, and species variation in prevalence of influenza A viruses in wild migratory birdsHuman and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammalsCharacterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gullsAvian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndromeDeveloping Universal Influenza Vaccines: Hitting the Nail, Not Just on the HeadOptimisations and Challenges Involved in the Creation of Various Bioluminescent and Fluorescent Influenza A Virus Strains for In Vitro and In Vivo ApplicationsPlasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysisCross-reactive CD8 + T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A virusesH5N1 Virus Attachment to Lower Respiratory TractAvian influenza a virus in wild birds in highly urbanized areasAssessment of the antiviral properties of recombinant porcine SP-D against various influenza A viruses in vitroA recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virusAirborne transmission of influenza A/H5N1 virus between ferretsInfluenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.Newer respiratory virus infections: human metapneumovirus, avian influenza virus, and human coronaviruses.Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strainInfluenza A virus (H5N1) infection in cats causes systemic disease with potential novel routes of virus spread within and between hosts.Human cytotoxic T lymphocytes directed to seasonal influenza A viruses cross-react with the newly emerging H7N9 virusGenomewide analysis of reassortment and evolution of human influenza A(H3N2) viruses circulating between 1968 and 2011Advances in influenza vaccination.Novel G3/DT adjuvant promotes the induction of protective T cells responses after vaccination with a seasonal trivalent inactivated split-virion influenza vaccine.Influenza virus-specific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development.Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial.Virus-specific T cells as correlate of (cross-)protective immunity against influenza.Pathogenesis of infection with 2009 pandemic H1N1 influenza virus in isogenic guinea pigs after intranasal or intratracheal inoculation.Identification of amino acid substitutions supporting antigenic change of influenza A(H1N1)pdm09 viruses.Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.Correlates of protection: novel generations of influenza vaccines.BCG Vaccination Enhances the Immunogenicity of Subsequent Influenza Vaccination in Healthy Volunteers: A Randomized, Placebo-Controlled Pilot Study.Low Virulence and Lack of Airborne Transmission of the Dutch Highly Pathogenic Avian Influenza Virus H5N8 in Ferrets.Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara.Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus.Virus replication kinetics and pathogenesis of infection with H7N9 influenza virus in isogenic guinea pigs upon intratracheal inoculation.Heterosubtypic immunity to H7N9 influenza virus in isogenic guinea pigs after infection with pandemic H1N1 virus.Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets.Influenza virus CTL epitopes, remarkably conserved and remarkably variable.MVA-based H5N1 vaccine affords cross-clade protection in mice against influenza A/H5N1 viruses at low doses and after single immunization.Animal models for the preclinical evaluation of candidate influenza vaccines.Introduction of virulence markers in PB2 of pandemic swine-origin influenza virus does not result in enhanced virulence or transmission.Seasonal and pandemic human influenza viruses attach better to human upper respiratory tract epithelium than avian influenza viruses.
P50
Q21089625-4C46129C-012D-42AF-8298-95EF949F4F28Q22255464-1FCB3057-AAA4-41AD-B89E-4B0232CF9B76Q24556678-58B01308-CA97-404D-A230-F4E6D1E725F2Q24608173-16105AD4-A47C-479B-8C73-21F34FF0F388Q26783897-89117C56-847A-4F70-9D81-D5B95E625F54Q27301941-7D2F8FEA-CAC1-4D91-B481-56FADE39F2D8Q27335814-A61B3A3E-E59D-44CF-A849-EBF8FACEA728Q27663289-426842E9-C54B-41D6-9AC6-0A59A6EBA74DQ28303460-8E76D108-B5F9-448A-BF7E-D59A036CB687Q28727914-065E75F2-491E-4148-A759-0B592A9F01ECQ28740380-1B777D84-D2BE-48FE-AC9B-079910889E23Q28740740-524C4837-5079-4F70-A4A7-8EB133B4E3D8Q29619970-1FE5D8A7-D7D1-4170-9956-BCA4AF49C053Q30243961-94BF6323-1AE9-4F90-A39B-89C01DFAD9D1Q30350277-56180AC5-BA3F-4A0E-92EE-1CB1CA573FC3Q30351385-2274F691-868C-4554-B673-B299EF32258EQ30352436-E895C23E-BE30-4110-A1D8-25560DE81091Q30355817-A05FE52C-A4ED-4965-A585-597A5CDC0FDFQ30357267-F1FFDC9C-9E7F-41BB-B41A-B52F021B0A72Q30364315-DC23B366-AB11-4FCB-832A-9F3A8722BC8EQ30365882-2068FED9-9769-43AE-9F80-353A4C45B4F6Q30366558-F4F9741A-67CC-452D-BDD6-C3930934CEA4Q30369228-00A5ED64-D13E-4D2E-84F4-81C6A0996619Q30369605-38CC4AAF-CD96-4869-8FCE-BB920E29100AQ30370383-4FEDEEFD-F250-4019-8EA0-83CCDD1A89D3Q30370987-55D75402-71DA-4121-BCE8-003FD748CD42Q30372918-70DF6FA7-6D90-4C01-88BD-E22EFF2A6933Q30375051-3BB3E77F-13B7-49FA-BA3E-30AED58FB1CFQ30375629-C2460E24-4627-4092-8148-10EBA79E92F2Q30375847-4521252F-A111-4E6E-B3CC-AA8442B11FE2Q30375979-0E030F1E-5569-4BE7-986C-1682A9388A57Q30377041-908D2B49-15FA-47DC-85FD-63B37CBFC92FQ30378373-FAE83DBD-5D03-450B-98E1-48E919C21B8AQ30378538-23B29A52-7AB3-4105-B5AB-DD8A0AD25934Q30378627-22CCBA55-5CD6-4BD8-B14F-10BB03C72BCCQ30381769-6D227288-57C2-445D-BB76-46405EA6B440Q30382567-4E3AFD16-0A0B-4AD2-8BF3-83FF0E597D6DQ30383623-958EE62B-F939-4115-85B3-1BFBA67281A3Q30385332-5377A1F8-828F-47CD-B26A-4484EFD19DCEQ30385814-22BAFBB3-3EF6-45F5-9141-581BAD750BDA
P50
description
Dutch virologist
@en
Dutch virologist
@en-ca
Dutch virologist
@en-gb
immunoloog
@nl
niederländischer Virologe und Immunologe
@de
virólogo neerlandés
@es
عالم فيروسات هولندي
@ar
name
Guus Rimmelzwaan
@ast
Guus Rimmelzwaan
@de
Guus Rimmelzwaan
@en
Guus Rimmelzwaan
@es
Guus Rimmelzwaan
@nl
type
label
Guus Rimmelzwaan
@ast
Guus Rimmelzwaan
@de
Guus Rimmelzwaan
@en
Guus Rimmelzwaan
@es
Guus Rimmelzwaan
@nl
prefLabel
Guus Rimmelzwaan
@ast
Guus Rimmelzwaan
@de
Guus Rimmelzwaan
@en
Guus Rimmelzwaan
@es
Guus Rimmelzwaan
@nl
P1006
P214
P227
P1006
P106
P1960
hNXOMWEAAAAJ
P21
P213
0000 0003 9418 966X
P214
P227
1161839321
P31
P569
1959-01-01T00:00:00Z
P7859
viaf-288617957